A Phase 2, Double-Blind, Placebo-Controlled, Randomized, International, Multicenter Study of Oral TAC 101 [amsilarotene] as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy.

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Randomized, International, Multicenter Study of Oral TAC 101 [amsilarotene] as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Amsilarotene (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 17 Mar 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top